Products
Garetatug Biosimilar Antibody-Drug Conjugate (Claudin-18) for Research
Cat No.: GMP-Bios-INN-1214
Anti-CLDN18 therapeutic antibody (Pre-made Garetatug biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Garetatug (development code SHR-1904) is a humanized monoclonal antibody-drug conjugate targeting claudin 18.2 (CLDN18). It is developed for solid tumors. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1214-1mg | 1mg | 4635 |
| GMP-Bios-INN-1214-10mg | 10mg | |
| GMP-Bios-INN-1214-100mg | 100mg | |
| GMP-Bios-INN-1214-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Garetatug biosimilar, Whole mAb ADC, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody |
| INN Name | Garetatug |
| Target | CLDN18 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
